MedCity News November 19, 2024
The DEA recently announced the third extension of Covid-19 flexibilities for the virtual prescribing of controlled substances. Telehealth advocates applaud this move but remain hopeful for a more permanent solution in the future.
Several telehealth advocates are coming out in support of the Drug Enforcement Administration’s (DEA) third extension of Covid-19 telehealth flexibilities for the prescribing of controlled substances. However, they argue that more work needs to be done to make these flexibilities permanent.
The flexibilities, introduced in 2020, permit providers to prescribe some controlled substances virtually without first requiring an in-person visit. These flexibilities were set to expire at the end of the year, but will now expire at the end of 2025 with the third extension announced last...
Today's Sponsors
Today's Sponsor